Ishikawa T, et al. - In this study, survival outcomes of neoadjuvant chemotherapy (CT) with zoledronic acid (ZOL) for HER2-negative breast cancer were reported. Researchers observed no improvement in disease-free survival (DFS) with ZOL in combination with CT. However, in triple-negative (TN) breast cancer, the improvement of the pathologic complete response rate was translated to survival outcomes. In postmenopausal patients, the short-term application of ZOL may not be sufficient to improve the outcome.